CRG-002 / Celregen Therapeutics - LARVOL DELTA

First-in-human transplantation of CRG-002, an iPSC-derived universal islet product for type 1 diabetes (EASD 2026) - P1 | "CRG-002 achieves potent, durable glycemic control with an excellent safety profile in the first T1D patient. These proof-of- concept findings strongly support further clinical development of CRG-002 as a scalable functional cure for type 1 diabetes."

First-in-human • Late-breaking abstract • P1 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus